A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer.
Susan DentDean FergussonOlexiy AseyevCarol StoberGregory PondArif A AwanSharon F McGeeTerry L NgDemetrios SimosLisa VandermeerDeanna SaundersJohn F HiltonBrian HuttonMark J ClemonsPublished in: Current oncology (Toronto, Ont.) (2021)
Cardiac monitoring every 4 months was deemed non-inferior to that every 3 months in patients with HER2-positive EBC being treated with trastuzumab-based therapy. Given its costs and inconvenience, cardiac monitoring every 4 months should be considered standard practice. Registration: NCT02696707, 18 February 2016.